Blood cancer journal

Keyphrases

Publications

volume 13, number 1, 2023

Aldo A Acosta-Medina, Isla McKerrow Johnson, Radhika Bansal, Matthew Hathcock, Saad Sirop Kenderian, Urshila Durani, Arushi Khurana, Yucai Wang, Jonas Paludo, Jose C Villasboas Bisneto, N Nora Bennani, Patrick B Johnston, Stephen M Ansell, Yi Lin, Hassan B Alkhateeb
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood cancer journal 13 (1) (2023)
Aldo A Acosta-Medina, Isla McKerrow Johnson, Radhika Bansal, Matthew Hathcock, Saad Sirop Kenderian, Urshila Durani, Arushi Khurana, Yucai Wang, Jonas Paludo, Jose C Villasboas Bisneto, N Nora Bennani, Patrick B Johnston, Stephen M Ansell, Yi Lin, Hassan B Alkhateeb
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood cancer journal 13 (1) (2023)
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-María Ribera, Renato Bassan, Andrey N Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foà, Alessandro Rambaldi
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood cancer journal 13 (1) (2023)
Keiji Kurata, Anna-James Bott, Mark A Tye, Leona Yamamoto, Mehmet Kemal Samur, Yu-Tzu Tai, James E Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C Christianson, N Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C Anderson, Udo Oppermann
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. Blood cancer journal 13 (1) (2023)
José Luis Piñana, Lourdes Vázquez, Marisa Calabuig, Lucia López-Corral, Gabriel Martin-Martin, Lucia Villalon, Gabriela Sanz-Linares, Venancio Conesa, Andrés Sanchez-Salinas, Beatriz Gago, Ana Facal, Irene Risco-Gálvez, María T Olave, Ildefonso Espigado, Javier Lopez-Jimenez, Jose-Ángel Hernández-Rivas, Alejandro Avendaño-Pita, Ignacio Arroyo, Elena Ferrer, García-Cadenas Irene, Clara González-Santillana, Alicia Roldán Pérez, Blanca Ferrer, Manuel Guerreiro, María Suarez-Lledó, Angela Camara, Diana Campos-Beltrán, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano, null null, Rodrigo Martino Bofarull
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood cancer journal 13 (1) (2023)
Elias Karl Mai, Stefanie Huhn, Kaya Miah, Alexandra M Poos, Christof Scheid, Katja C Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W Blau, Mathias Hänel, Hans J Salwender, Axel Benner, Marc-Steffen Raab, Hartmut Goldschmidt, Niels Weinhold
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood cancer journal 13 (1) (2023)
José Luis Piñana, Lourdes Vázquez, Marisa Calabuig, Lucia López-Corral, Gabriel Martin-Martin, Lucia Villalon, Gabriela Sanz-Linares, Venancio Conesa, Andrés Sanchez-Salinas, Beatriz Gago, Ana Facal, Irene Risco-Gálvez, María T Olave, Ildefonso Espigado, Javier Lopez-Jimenez, Jose-Ángel Hernández-Rivas, Alejandro Avendaño-Pita, Ignacio Arroyo, Elena Ferrer, García-Cadenas Irene, Clara González-Santillana, Alicia Roldán Pérez, Blanca Ferrer, Manuel Guerreiro, María Suarez-Lledó, Angela Camara, Diana Campos-Beltrán, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano, null null, Rodrigo Martino Bofarull
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood cancer journal 13 (1) (2023)
Yingling Zu, Ruirui Gui, Zhen Li, Juan Wang, Yanli Zhang, Fengkuan Yu, Huifang Zhao, Xinrong Zhan, Zhongliang Wang, Pengtao Xing, Xianjing Wang, Huili Wang, Yongping Song, Jian Zhou
Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial. Blood cancer journal 13 (1) (2023)
Aldo A Acosta-Medina, Isla McKerrow Johnson, Radhika Bansal, Matthew Hathcock, Saad Sirop Kenderian, Urshila Durani, Arushi Khurana, Yucai Wang, Jonas Paludo, Jose C Villasboas Bisneto, N Nora Bennani, Patrick B Johnston, Stephen M Ansell, Yi Lin, Hassan B Alkhateeb
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
Urvi A Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M Birmann, Saad Z Usmani, Nicole Gormley, Catherine R Marinac, Carl Ola Landgren
Extreme body mass index and survival in newly diagnosed multiple myeloma patients. Blood cancer journal 13 (1) (2023)
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis V Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A Kyle, Sundararajan Vincent Rajkumar, Shaji K Kumar
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. Blood cancer journal 13 (1) (2023)
Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D Lynne Smith, Alex F Herrera, Stephen E F Spurgeon, Byung Park, Lionel D Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V Danilov
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood cancer journal 13 (1) (2023)
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-María Ribera, Renato Bassan, Andrey N Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foà, Alessandro Rambaldi
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood cancer journal 13 (1) (2023)
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, Shinsuke Iida, Philippe Moreau, Shaji K Kumar, Philip Twumasi-Ankrah, Miguel Villarreal, Ajeeta B Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios- Athanasios Dimopoulos, Sundararajan Vincent Rajkumar
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. Blood cancer journal 13 (1) (2023)
Naseema Gangat, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Animesh Pardanani, Ayalew Tefferi
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood cancer journal 13 (1) (2023)
Xavier Cheng-Hong Tsai, Kuo-Jui Sun, Min-Yen Lo, Feng-Ming Tien, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Yi-Kuang Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Ming-Chih Liu, Chia-Wen Liu, Chien-Chin Lin, Ming Yao, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood cancer journal 13 (1) (2023)
Naseema Gangat, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Animesh Pardanani, Ayalew Tefferi
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
Xavier Cheng-Hong Tsai, Kuo-Jui Sun, Min-Yen Lo, Feng-Ming Tien, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Yi-Kuang Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Ming-Chih Liu, Chia-Wen Liu, Chien-Chin Lin, Ming Yao, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood cancer journal 13 (1) (2023)
Urvi A Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M Birmann, Saad Z Usmani, Nicole Gormley, Catherine R Marinac, Carl Ola Landgren
Extreme body mass index and survival in newly diagnosed multiple myeloma patients. Blood cancer journal 13 (1) (2023)
Kelly von Beck, Troy von Beck, P Brent Ferrell, Alexander G Bick, Ashwin Kishtagari
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood cancer journal 13 (1) (2023)
Keiji Kurata, Anna-James Bott, Mark A Tye, Leona Yamamoto, Mehmet Kemal Samur, Yu-Tzu Tai, James E Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C Christianson, N Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C Anderson, Udo Oppermann
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. Blood cancer journal 13 (1) (2023)
Yingling Zu, Ruirui Gui, Zhen Li, Juan Wang, Yanli Zhang, Fengkuan Yu, Huifang Zhao, Xinrong Zhan, Zhongliang Wang, Pengtao Xing, Xianjing Wang, Huili Wang, Yongping Song, Jian Zhou
Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial. Blood cancer journal 13 (1) (2023)
Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D Lynne Smith, Alex F Herrera, Stephen E F Spurgeon, Byung Park, Lionel D Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V Danilov
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood cancer journal 13 (1) (2023)
Yingling Zu, Ruirui Gui, Zhen Li, Juan Wang, Yanli Zhang, Fengkuan Yu, Huifang Zhao, Xinrong Zhan, Zhongliang Wang, Pengtao Xing, Xianjing Wang, Huili Wang, Yongping Song, Jian Zhou
Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial. Blood cancer journal 13 (1) (2023)
Elias Karl Mai, Stefanie Huhn, Kaya Miah, Alexandra M Poos, Christof Scheid, Katja C Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W Blau, Mathias Hänel, Hans J Salwender, Axel Benner, Marc-Steffen Raab, Hartmut Goldschmidt, Niels Weinhold
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood cancer journal 13 (1) (2023)
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis V Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A Kyle, Sundararajan Vincent Rajkumar, Shaji K Kumar
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. Blood cancer journal 13 (1) (2023)
Kelly von Beck, Troy von Beck, P Brent Ferrell, Alexander G Bick, Ashwin Kishtagari
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood cancer journal 13 (1) (2023)
Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood cancer journal 13 (1) (2023)
José Luis Piñana, Lourdes Vázquez, Marisa Calabuig, Lucia López-Corral, Gabriel Martin-Martin, Lucia Villalon, Gabriela Sanz-Linares, Venancio Conesa, Andrés Sanchez-Salinas, Beatriz Gago, Ana Facal, Irene Risco-Gálvez, María T Olave, Ildefonso Espigado, Javier Lopez-Jimenez, Jose-Ángel Hernández-Rivas, Alejandro Avendaño-Pita, Ignacio Arroyo, Elena Ferrer, García-Cadenas Irene, Clara González-Santillana, Alicia Roldán Pérez, Blanca Ferrer, Manuel Guerreiro, María Suarez-Lledó, Angela Camara, Diana Campos-Beltrán, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano, null null, Rodrigo Martino Bofarull
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood cancer journal 13 (1) (2023)
Hira S Mian, Arleigh McCurdy, Smith Giri, Shakira J Grant, Bram Rochwerg, Erica Winks, Ashley E Rosko, Monika Engelhardt, Charlotte Pawlyn, Curly T C M Morris, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M Wildes
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood cancer journal 13 (1) (2023)
Elias Karl Mai, Stefanie Huhn, Kaya Miah, Alexandra M Poos, Christof Scheid, Katja C Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W Blau, Mathias Hänel, Hans J Salwender, Axel Benner, Marc-Steffen Raab, Hartmut Goldschmidt, Niels Weinhold
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood cancer journal 13 (1) (2023)
Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D Lynne Smith, Alex F Herrera, Stephen E F Spurgeon, Byung Park, Lionel D Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V Danilov
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood cancer journal 13 (1) (2023)
Hira S Mian, Arleigh McCurdy, Smith Giri, Shakira J Grant, Bram Rochwerg, Erica Winks, Ashley E Rosko, Monika Engelhardt, Charlotte Pawlyn, Curly T C M Morris, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M Wildes
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood cancer journal 13 (1) (2023)
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis V Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A Kyle, Sundararajan Vincent Rajkumar, Shaji K Kumar
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. Blood cancer journal 13 (1) (2023)
Naseema Gangat, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Animesh Pardanani, Ayalew Tefferi
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood cancer journal 13 (1) (2023)
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, Shinsuke Iida, Philippe Moreau, Shaji K Kumar, Philip Twumasi-Ankrah, Miguel Villarreal, Ajeeta B Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios- Athanasios Dimopoulos, Sundararajan Vincent Rajkumar
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. Blood cancer journal 13 (1) (2023)
Kelly von Beck, Troy von Beck, P Brent Ferrell, Alexander G Bick, Ashwin Kishtagari
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood cancer journal 13 (1) (2023)
Urvi A Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M Birmann, Saad Z Usmani, Nicole Gormley, Catherine R Marinac, Carl Ola Landgren
Extreme body mass index and survival in newly diagnosed multiple myeloma patients. Blood cancer journal 13 (1) (2023)
Elias Karl Mai, Stefanie Huhn, Kaya Miah, Alexandra M Poos, Christof Scheid, Katja C Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W Blau, Mathias Hänel, Hans J Salwender, Axel Benner, Marc-Steffen Raab, Hartmut Goldschmidt, Niels Weinhold
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood cancer journal 13 (1) (2023)
Enze Liu, Nathan Becker, Parvathi Sudha, Chuanpeng Dong, Yunlong Liu, Jonathan J Keats, Gareth Morgan, Brian A Walker
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway. Blood cancer journal 13 (1) (2023)
Hira S Mian, Arleigh McCurdy, Smith Giri, Shakira J Grant, Bram Rochwerg, Erica Winks, Ashley E Rosko, Monika Engelhardt, Charlotte Pawlyn, Curly T C M Morris, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M Wildes
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood cancer journal 13 (1) (2023)
Hira S Mian, Arleigh McCurdy, Smith Giri, Shakira J Grant, Bram Rochwerg, Erica Winks, Ashley E Rosko, Monika Engelhardt, Charlotte Pawlyn, Curly T C M Morris, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M Wildes
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood cancer journal 13 (1) (2023)
Naseema Gangat, Kebede H Begna, Aref A Al-Kali, William Joseph Hogan, Mark R Litzow, Animesh Pardanani, Ayalew Tefferi
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood cancer journal 13 (1) (2023)
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-María Ribera, Renato Bassan, Andrey N Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foà, Alessandro Rambaldi
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood cancer journal 13 (1) (2023)
Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D Lynne Smith, Alex F Herrera, Stephen E F Spurgeon, Byung Park, Lionel D Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V Danilov
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood cancer journal 13 (1) (2023)
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, Shinsuke Iida, Philippe Moreau, Shaji K Kumar, Philip Twumasi-Ankrah, Miguel Villarreal, Ajeeta B Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios- Athanasios Dimopoulos, Sundararajan Vincent Rajkumar
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. Blood cancer journal 13 (1) (2023)
Keiji Kurata, Anna-James Bott, Mark A Tye, Leona Yamamoto, Mehmet Kemal Samur, Yu-Tzu Tai, James E Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C Christianson, N Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C Anderson, Udo Oppermann
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. Blood cancer journal 13 (1) (2023)
Xavier Cheng-Hong Tsai, Kuo-Jui Sun, Min-Yen Lo, Feng-Ming Tien, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Yi-Kuang Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Ming-Chih Liu, Chia-Wen Liu, Chien-Chin Lin, Ming Yao, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood cancer journal 13 (1) (2023)